ArticleFrontiers in oncology2026
Association between treatment decisions and survival outcomes in lung cancer patients under a multidisciplinary team model: the impact of MDT-recommended treatment plans on treatment completion rates, survival time, and treatment conversion.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The complexity of lung cancer management requires coordinated care. This study aimed to evaluate the impact of Multidisciplinary Team (MDT)-recommended treatment plans on the treatment course and survival outcomes of lung cancer patients. Methods: This single-center, retrospective cohort study enrolled consecutive patients with primary lung cancer who were initially diagnosed and received first anti-cancer treatment between January 1, 2020, and January 30, 2023. Patients were categorized into MDT (n=115) or non-MDT (n=105) groups based on whether the initial treatment decision was made via a formal MDT discussion. Key measures included treatment completion rate, treatment conversion, overall survival (OS), progression-free survival (PFS), and safety profiles. Follow-up data were collected until July 31, 2025. Results: The MDT group demonstrated a significantly higher rate of completing the initial treatment as planned (86.09% vs. 68.57%, P = 0.002), a lower treatment conversion rate (19.13% vs. 39.05%, P = 0.001), and a longer time to conversion (8.41 vs. 5.16 months, P<0.001). Patients in the MDT group had significantly longer median OS (45.21 vs. 28.64 months, P<0.001) and PFS (19.80 vs. 13.53 months, P<0.001). Multivariate analyses confirmed MDT participation as an independent factor associated with improved OS (HR = 0.605, P = 0.009) and a higher likelihood of treatment completion (OR = 3.438, P = 0.002). Conclusion: The MDT model is associated with better treatment adherence, delayed treatment conversion, and significantly improved survival outcomes in lung cancer patients, and facilitates more precise initial treatment selection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.